Articles Referencing MDVN
Bayer's Xofigo Cleared in the US - Analyst Blog
5/16/2013, 6:30 pm from Zacks.com in Investing, Business, Stocks
Bayer 's ( BAYRY ) HealthCare
segment recently received encouraging news as the US Food and Drug
Administration (FDA) approved its oncology drug Xofigo (radium 223
dichloride). Xofigo was... Read >>
Medivation Loss Narrower Than Expected - Analyst Blog
5/13/2013, 9:40 am from Zacks.com in Investing, Business, Stocks
Medivation Inc. ( MDVN ) reported a
first-quarter loss of 36 cents per share, narrower than the Zacks
Consensus Estimate of a loss of 41 cents per share. However, the
company recorded... Read >>
After-Hours Earnings Report for May 9, 2013 : PCLN, PSA, NVDA, CFN, AGO, MDVN, GXP, SLXP, AL, BID, MDRX, SF
5/9/2013, 2:00 pm from NASDAQ.com News in News Headlines, Earnings
The following companies are expected to report earnings after
hours on 05/09/2013. Visit our Earnings
Calendar for a full list of expected earnings releases. priceline.com Incorporated ( ... Read >>
Pharmacyclics Inc. (PCYC): Today's Most Compelling Stock Buy
5/7/2013, 1:53 pm from David Moenning in Investing, Investing Ideas, Stocks, US Markets
SoTM Bull's Eye Report - Today's Most Compelling Buy Tuesday, May 7, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the... Read >>
Eylea Drives Earnings at Regeneron - Analyst Blog
5/3/2013, 2:35 pm from Zacks.com in Investing, Business, Earnings, Stocks
Regeneron Pharmaceuticals Inc .'s ( REGN ) first quarter
2013 earnings (excluding special items but including stock-based
compensation) of $1.30 per share breezed past the Zacks... Read >>
Narrower-Than-Expected Loss at Incyte - Analyst Blog
5/3/2013, 2:31 pm from Zacks.com in Investing, Business, Stocks
Incyte Corporation ( INCY ) reported a loss
of 12 cents per share in the first quarter of 2013, narrower than
the loss of 13 cents hinted by the Zacks Consensus Estimate. The
company's... Read >>
Wider-Than-Expected Loss at Pharmacyclics - Analyst Blog
5/2/2013, 2:26 pm from Zacks.com in Investing, Business, Stocks
Pharmacyclics Inc. 's ( PCYC ) first quarter
2013 loss of 73 cents per share was wider than the year-ago loss of
19 cents and the loss of 8 cents hinted at by the Zacks Consensus
Estimate.... Read >>
Polycyclics Inc. (PCYC): Today's Most Compelling Stock Pick
4/26/2013, 3:20 pm from David Moenning in Investing, Investing Ideas, Stocks, US Markets
SoTM Bull's Eye Report - Today's Most Compelling Buy Friday, April 26, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the... Read >>
Aragon Pharma's ARN-509 Is No Near-Term Threat to Medivation
4/23/2013, 11:55 am from Minyanville in Investing, Stocks
If I don't miss my guess, Medivation ( MDVN ) shares will
come under pressure today based upon an 8-K it filed on Monday. The
decline, if it happens, reflects a basic lack of understanding... Read >>
Astellas/MDVN Provide Update on Xtandi - Analyst Blog
4/2/2013, 5:24 pm from Zacks.com in Investing, Business, Stocks
Astellas Pharma Inc. ( ALPMY ) and partner
Medivation, Inc. ( MDVN ) recently
announced that the companies have established an updated interim
analysis plan for an ongoing phase III... Read >>
Good News for Nymox's Pipeline - Analyst Blog
3/21/2013, 6:23 pm from Zacks.com in Investing, Business, Stocks
Positive news flowed in at Nymox Pharmaceutical
Corporation ( NYMX ) recently when
the Independent Data Monitoring Committee (IDMC) reported the third
positive analysis of safety data from... Read >>
Merck-Luminex' Alzheimer's Collaboration - Analyst Blog
3/19/2013, 4:47 pm from Zacks.com in Investing, Business, Stocks
Merck ( MRK ) recently entered
into an agreement with Luminex Corporation ( LMNX ) for the
development of a companion diagnostic device that will be used to
screen patients for... Read >>
Pluristem & UTHR Progress with PLX-PAD - Analyst Blog
3/4/2013, 5:25 pm from Zacks.com in Investing, Business, Stocks
Israel-based Pluristem Therapeutics Inc. ( PSTI ) recently
announced that partner United Therapeutics
Corporation ( UTHR ) intends to
commence a phase I study in Australia using... Read >>
Medivation Beats 4Q Expectations - Analyst Blog
3/1/2013, 9:00 am from Zacks.com in Investing, Business, Stocks
Medivation Inc. ( MDVN ) reported a
fourth-quarter loss of 43 cents per share, narrower than the Zacks
Consensus Estimate of a loss of 51 cents per share but well above
the year-ago loss of... Read >>
Pipeline Advances at Isis Pharma - Analyst Blog
2/28/2013, 4:28 pm from Zacks.com in Investing, Business, Stocks
Isis Pharmaceuticals, Inc. ( ISIS ) recently
announced that it has initiated a phase II study (n = 20) to
evaluate the safety and efficacy of its paroxysmal atrial
fibrillation (AF)... Read >>